



Patent Docket P0987R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Martin M. Bednar et al.

Serial No.: 08/788,800

Filed: January 22, 1997

For: ANTI-CD18 ANTIBODIES IN STROKE

Group Art Unit: 1806

Examiner: P. Gambel

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

March 2, 1998

Sandra K. T. Sullivan
Sandra K. T. Sullivan

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents
Washington, D.C. 20231

RECEIVED

MAR - 9 1998

Sir:

MATRIX CUSTOMER
SERVICE CENTER

In response to the Office Action dated October 2, 1997, the period for response having been extended as a result of the enclosed Petition for a two month Extension of Time and requisite fee, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

IN THE SPECIFICATION:

On page 13, line 12, please insert --(SEQ ID NO:11)-- at the end of the sequence and before the period.

IN THE CLAIMS:

In claim 1, before "mammal" please insert --human--.

In claim 10, line 2, please replace "mins" with --minutes--.

11. (Amended) The method of claim 1 wherein the anti-CD18 antibody is humanized H52 antibody comprising heavy chain sequence of SEQ ID NO:10 and light chain sequence of SEQ ID NO:11.

Please cancel claims 13 and 14 without prejudice or disclaimer of the subject matter therein.

In claim 15, line 7, please delete "antagonist".